Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has announced the expansion of internal capabilities to execute critical stages of its ACCUM-enabled antibody drug conjugates (ADC) development pipeline.
According to Defence, the company has strengthened its purification, analytical characterization, conjugation development, and quality control capabilities (QC), while enhancing cellular testing and potency evaluation workflows within a more structured stage-gated framework to better support the advancement of its ADC partnership programs.
In a statement, Mark Lambermon, PhD, head of quality and operations at Defence, commented, “By strengthening our internal QC, analytical, and conjugation capabilities, Defence is positioning itself to become a leading authority in the development and controlled manufacture of ACCUM-enabled ADCs. Our focus is to establish robust, reproducible, and quality-driven processes that support the consistent generation of high-quality ACCUM-ADC candidates for our partnership programs.”
